Crispr Therapeutics vs Prelude Therapeutics
Prelude Therapeutics is the larger business, with $12.1m of revenue in fiscal 2025 against $3.5m for Crispr Therapeutics (3.5 times as much). Prelude Therapeutics grew faster (73.4% against -90.6%). Prelude Therapeutics kept more of each dollar of sales as profit: a net margin of -819.6% against -16569.8%. Crispr Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Crispr TherapeuticsCRSP, 2025 | Prelude TherapeuticsPRLD, 2025 |
|---|---|---|
| Revenue | $3.5m | $12.1m |
| Revenue growth | -90.6% | 73.4% |
| Net income | −$582m | −$99.5m |
| Operating margin | -18933.6% | -861.3% |
| Net margin | -16569.8% | -819.6% |
| Return on equity | -30.2% | -99.5% |
| Free cash flow | −$346m | −$56.4m |
| Cash | $348m | $35.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 79 |
| Market value | $4.83bn | $372m |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | — |
| Insider trades, 12 months | 0 buys, 30 sales | 4 buys, 0 sales |